Novo Nordisk's Downturn Amid Pricing Cuts and Patent Worries

22 days ago

"What's it doing today? Yeah, a company that was a big winner and has now turned into a loser. Unfortunately, it cut the listing price of its obesity drug WGOI by half in some parts of China. The Danish drug maker is getting ready for a potential flood of copycats as its semiglutide patent nears expiration. And it is now down 40% year to date."

The commentary highlights Novo Nordisk's recent struggles following a sharp price cut of its obesity drug in China and looming patent expiration, resulting in a significant 40% decline year to date. These factors combined indicate mounting competitive and regulatory pressures.

Related Stocks